Greenwich LifeSciences Stock Surges on FDA Approval for Breast Cancer Trial

Greenwich LifeSciences (GLSI) shares jump 42% after FDA approves commercial GP2 for Phase III breast cancer prevention trial, reducing regulatory risks ahead of license application.